MI

Medrhythms, Inc.

www.medrhythms.com link_icon

MedRhythms, Inc. - Company Market Research Report



Company Overview



Name:


  • MedRhythms, Inc.


Mission of the Company:


  • Mission: The mission of MedRhythms is to positively impact the lives of those living with neurologic injury and disease by developing next-generation neurotherapeutics that harness the power of music and technology to redefine what’s possible in brain health for patients around the world.


Founding Information:


  • Year Founded: No information is available

  • Founders: Brian Harris (CEO & Founder), Owen McCarthy (President & Founder)


Key People:


  • Key People:

  • Brian Harris: CEO & Founder

  • Owen McCarthy: President & Founder

  • Board of Directors:

  • Christopher Harris, Stephen Bruso, Peter Werth, Ray Pawlicki, Bill Mckee (Board Observer), Jean Hoffman


Company Headquarters:


  • Location: 183 Middle St, Portland, ME 04101


Number of Employees:


  • No information is available


Revenue:


  • No information is available


Known For:


  • MedRhythms is known for pioneering next-generation neurotherapeutics designed to improve walking, mobility, and related functional outcomes through a proprietary patented technology platform that combines music and technology.


Products



Product Offerings:


  • InTandem™:

  • A digital therapeutic system for people with gait impairment due to chronic stroke, leveraging music and technology to improve mobility.


High-Level Product Description:


  • InTandem™: Available by prescription, aimed at treating chronic stroke walking impairment through rhythmic auditory stimulation (RAS) to provide auditory stimuli, improving walking entrainment and functionality.


Key Features:


  • The technology platform integrates sensors and music, through proprietary algorithms, to capture real-time gait data and offer personalized rhythmic stimuli.


Recent Developments



Recent Company Developments:


  • November 8, 2023: Partnership with Lovell to provide InTandem™ for veterans and military personnel with walking impairments due to stroke.


New Product Launches:


  • October 16, 2023: InTandem™ is available by prescription for adults with chronic stroke walking impairment.


New Features and Partnerships:


  • July 6, 2023: FDA listing of InTandem™ (MR-001) for improving walking and ambulation in adults with chronic stroke.

  • Ongoing clinical trials with top institutions like Cleveland Clinic and Massachusetts General Hospital for pipeline products addressing multiple sclerosis and Parkinson’s disease.


Strategic Alliances:


  • Partnership with Universal Music Group to integrate music in neurotherapeutic programs.


Conclusion



This report highlights MedRhythms, Inc. as an innovative player in the neurotherapeutics industry, pushing the boundaries of rehabilitation through the unique confluence of music and technology. Their focus on rhythmic auditory stimulation and a robust pipeline focused on neurological disorders positions them strategically in the healthcare sector. Understanding the full potential of their offerings and developments could provide further insights into their growth trajectory and impact.